Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting

JAMA

Volumn 281, Issue 9, 1999, Pages 806-810

  Steinhubl, Steven R ^a   Tan, Walter A ^b   Foody, JoAnne M ^b   Topol, Eric J ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; HEPARIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY STENT; FEMALE; HUMAN; INCIDENCE; MALE; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0033518847     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.9.806     Document Type: Article

References (19)

1. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States: analysis of national mortality data, 1968-1991. Am J Hematol. 1995;50:84-90.
2. Berkowitz LR, Dalldorf FG, Blatt PM. Thrombotic thrombocytopenic purpura: a pathology review. JAMA. 1979;241:1709-1710.
3. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and a review of the literature. Medicine. 1981;60:413-428.
4. Page Y, Tardy B, ZeniF, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991;337:774-776.
5. Bennet CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med. 1998;128:541-544.
6. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084-1089.
7. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation. 1998;98:1802-1820.
8. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
9. Ellie E, Durrieu C, Besse P, Julien J, Cbipki-Benissan G. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke. 1992;23:922-923.
10. Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis. Am J Hematol. 1997;54:175-176.
11. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother. 1993;27:1060-1061.
12. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. N Engl J Med. 1997;337: 1245.
13. Chang JC, Shipstone A, Llenado-Lee MA. Post-operative thrombotic thrombocytopenic purpura following cardiovascular surgery. Am J Hematol. 1996; 53:11-17.
14. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombo-cytopenic purpura and hemolytic-uremic syndrome. Am J Med. 1989;87:9N-15N.
15. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339: 1585-1594.
16. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-deaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
17. Rice L, Tsai H-M, Chow TW, Moake JL. Increased von Willebrand factor (vWF)-platelet binding and decreased vWF-metalloproteinase in ticlopidine-induced thrombotic thrombocytopenic purpura [abstract]. Blood. 1998;2(suppl 1):706a.
18. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4:252-261.
19. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996; 348:1329-1339.